Histone Deacetylase Inhibitors in Combinatorial Anticancer Therapy. Dieser Artikel ist nicht verfügbar.Histone Deacetylase Inhibitors in Combinatorial Anticancer Therapy

This book reviews the latest developments in the design, synthesis, and molecular mechanism of action of Histone Deacetylase (HDAC) inhibitors in the context of potential cancer therapy. HDAC inhibitors are emerging as promising anticancer drug molecules that promote growth arrest, differentiation and apoptosis of cancer cells with tumor selective toxicity.

The book begins with an overview of various epigenetic modifying enzymes that are involved in cancer transition and progression; before exploring the potential of HDACs in cancer treatment. It provides a classification of HDAC inhibitors based on their structural attributes, and addresses HDAC-induced cytotoxicity..

Lastly, it discusses and assesses the rationale behind therapies that combine HDAC inhibitors with other anticancer agents to treat solid tumors. Given its scope, it offers a valuable resource for all researchers, clinicians, and students working in formulation, drug discovery, oncology, and personalized medicine.

Dr. Shabir Ahmad Ganai has formerly worked as Principal Investigator/Young Scientist in the University of Kashmir. He has over 9 years of working experience in the field of histone deacetylases and histone deacetylase inhibitors. He has published more than 24 articles in highly reputed international journals, 3 international book chapters and has authored a book. He is currently serving as a referee for various international journals like Scientific Reports, PLOS ONE, Medicinal Chemistry Research, Current Drug Targets, Current Topics in Medicinal Chemistry, and Journal of Agricultural and Food Chemistry (American Chemical Society Publications). He is a member of two international societies, including the Epigenetics Society.